AI-Powered ECG Detecting Culprit Vessel Blood Flow Abnormality in ACS
Launched by POWERFUL MEDICAL · Jul 26, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called AI ECG TIMI, is studying how an advanced artificial intelligence (AI) model can help doctors identify problems with blood flow in the heart of patients experiencing acute coronary syndrome (ACS). ACS includes serious conditions like heart attacks (STEMI and NSTEMI), where blood supply to the heart is suddenly reduced or blocked. The goal is to see if the AI can analyze electrocardiograms (ECGs)—a test that measures the electrical activity of the heart—and predict issues in blood flow just before a procedure called invasive coronary angiography, which doctors use to look at the heart's blood vessels.
To participate in this trial, patients need to be at least 18 years old and must be experiencing symptoms of ACS that require emergency medical attention, leading to an invasive coronary angiography. However, those who are having non-emergency procedures or have chronic heart problems won't be included. If eligible, participants can expect to have a standard ECG done shortly before their angiography, allowing researchers to gather important information about how well the AI can work in real-life situations. This study is currently recruiting participants from various locations, aiming to improve how doctors diagnose and treat heart conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with acute coronary syndromes undergoing invasive coronary angiography as clinically indicated.
- • Availability of a standard 12-lead ECG performed at invasive coronary angiogram before percutaneous coronary intervention (maximum within 15 min before vascular access).
- • Age ≥18 years.
- Exclusion Criteria:
- • Individuals presenting for a non-emergent (elective) cardiac catheterization.
- • Individuals presenting with chronic coronary syndrome (CCS) or stable angina symptoms.
- • Individuals without symptoms suspicious for acute coronary syndromes.
- • Individuals with contraindications for cardiac catheterization.
About Powerful Medical
Powerful Medical is a leading clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a focus on transformative therapies and cutting-edge technologies, the organization collaborates with healthcare professionals, institutions, and patients to conduct robust clinical trials that address unmet medical needs. Committed to ethical practices and regulatory compliance, Powerful Medical employs a multidisciplinary approach to ensure the safety and efficacy of its products, ultimately aiming to enhance patient outcomes and improve quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aalst, , Belgium
Graz, , Austria
Brugge, , Belgium
Hasselt, , Belgium
Bratislava, , Slovakia
Bruck An Der Mur, , Austria
Graz, , Austria
Chieti, , Italy
Rome, , Italy
Rome, , Italy
Patients applied
Trial Officials
Robert Herman, MD, PhD
Principal Investigator
Powerful Medical
Emanuele Barbato, MD, PhD
Study Chair
University of Roma La Sapienza
Jozef Bartunek, MD, PhD
Study Chair
Azorg Hospital, Aalst
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported